GLIGCA REPORT AT SPINE DEPARTMENT B – HCMC ORTHOPEDIC TRAUMA HOSPITAL

Chronic pain is a serious problem, causing many negative effects on the patient's daily life and mental health. Current treatment methods have not achieved the desired results, and can even cause side effects such as weight gain and fatigue with long-term use.

CPDP Medbolide Company has manufactured and distributed the product GLIGCA 25 (Milnacipran 25 mg). Milnacipran, the main ingredient of GLIGCA 25, has been shown to be safe and effective in the treatment of chronic pain and FM. The special feature of Milnacipran is that it does not cause cognitive impairment, does not cause weight gain, rarely causes sleep disturbances and is well tolerated. This makes it easier for patients to comply with treatment, thereby improving treatment effectiveness.

CPDP Medbolide Company held a product introduction event on November 2, 2023 at Spine Department B - Ho Chi Minh City Orthopedics Hospital. The presentation attracted the participation of more than 10 spine specialists. Through the introduction, Doctors had the opportunity to learn more deeply about GLIGCA and the benefits of the product. Doctors highly appreciate the clinical effectiveness, safety and treatment compliance of GLIGCA.

Medbolide has opened a new chapter in public health care with GLIGCA 25. GLIGCA 25 brings hope and significant improvement to the lives of people with chronic pain and FM syndrome.